Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Censoring Survival Data01:09

Censoring Survival Data

668
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
668
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

755
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
755
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

719
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
719
The Mantel-Cox Log-Rank Test01:19

The Mantel-Cox Log-Rank Test

1.3K
The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of...
1.3K
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

343
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
343
Cancer Survival Analysis01:21

Cancer Survival Analysis

844
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
844

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoprotein(a) lipidome and chronic kidney disease: Enrichment in triacylglycerols and diacylglycerols.

Journal of clinical lipidology·2026
Same author

Authors' Response to Comments by Di Tanna et al.

Statistics in medicine·2026
Same author

Lipoprotein(a) lipidome and diet: responses to reducing saturated fat intake in African Americans in a randomized trial.

Journal of lipid research·2026
Same author

Prevalence of undiagnosed hypertension and risk assessment using a validated survey in community-based screening in Amman, Jordan.

PloS one·2026
Same author

Meta-Analysis of Cost-Effectiveness.

Statistics in medicine·2026
Same author

Dietary and Physical Activity Habits of Potential Living Kidney Donors.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation·2026

Related Experiment Video

Updated: Apr 11, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.8K

Median-based incremental cost-effectiveness ratios with censored data.

Heejung Bang1, Hongwei Zhao2

  • 1a Division of Biostatistics, Department of Public Health Sciences , University of California , Davis , California , USA.

Journal of Biopharmaceutical Statistics
|May 27, 2015
PubMed
Summary

This study extends the median-based incremental cost-effectiveness ratio (ICER) method to handle censored data. This approach provides a more robust analysis of treatment cost-effectiveness, especially when patient data is incomplete.

Keywords:
CensoringICERcost-effectiveness analysismedian

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.5K
Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

16.2K

Related Experiment Videos

Last Updated: Apr 11, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.8K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.5K
Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

16.2K

Area of Science:

  • Health Economics
  • Biostatistics

Background:

  • Cost-effectiveness analysis (CEA) is crucial for treatment evaluation, complementing effectiveness measures.
  • The incremental cost-effectiveness ratio (ICER), using mean costs and quality-adjusted life years (QALYs), is a standard metric in CEA.
  • Median-based ICER has been proposed for sensitivity analyses, addressing limitations of mean-based approaches.

Purpose of the Study:

  • To extend the recently proposed median-based ICER method.
  • To incorporate methods for handling censored data within the median-based ICER framework.
  • To enhance the robustness of cost-effectiveness analyses when dealing with incomplete patient data.

Main Methods:

  • Development of statistical methods to compute median-based ICER with censored data.
  • Application of survival analysis techniques to cost and QALY data.
  • Simulation studies to evaluate the performance of the extended method.

Main Results:

  • The proposed method provides a valid extension for calculating median-based ICER with censored data.
  • Sensitivity analyses using the median-based ICER with censored data offer complementary insights to mean-based ICER.
  • The method demonstrates improved robustness in scenarios with data censoring.

Conclusions:

  • The extended median-based ICER method is a valuable tool for cost-effectiveness analysis, particularly with censored data.
  • This approach enhances the reliability of economic evaluations in healthcare.
  • Researchers can utilize this method for more comprehensive treatment value assessments.